Products
Pre-made Blinatumomab benchmark antibody ( Bispecific T-Cell Engager, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-074
Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-074-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-074-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-074-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-074-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody |
| INN Name | Blinatumomab |
| Target | CD19;CD3E |
| Format | Bispecific T-Cell Engager |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis |
| Conditions Approved | Precursor B-cell lymphoblastic leukaemia-lymphoma |
| Conditions Active | Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma |
| Conditions Discontinued | Chronic lymphocytic leukaemia |
| Development Tech | BiTE Technology |
